It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Biological degradation of natural product glycosides involves, alongside hydrolysis, β-elimination for glycosidic bond cleavage. Here, we discover an O-glycoside β-eliminase (OGE) from Agrobacterium tumefaciens that converts the C3-oxidized O-β-d-glucoside of phloretin (a plant-derived flavonoid) into the aglycone and the 2-hydroxy-3-keto-glycal elimination product. While unrelated in sequence, OGE is structurally homologous to, and shows effectively the same Mn2+ active site as, the C-glycoside deglycosylating enzyme (CGE) from a human intestinal bacterium implicated in β-elimination of 3-keto C-β-d-glucosides. We show that CGE catalyzes β-elimination of 3-keto O- and C-β-d-glucosides while OGE is specific for the O-glycoside substrate. Substrate comparisons and mutagenesis for CGE uncover positioning of aglycone for protonic assistance by the enzyme as critically important for C-glycoside cleavage. Collectively, our study suggests convergent evolution of active site for β-elimination of 3-keto O-β-d-glucosides. C-Glycoside cleavage is a specialized feature of this active site which is elicited by substrate through finely tuned enzyme-aglycone interactions.
Biological degradation of glycosides involves, alongside hydrolysis, β-elimination for glycosidic bond cleavage. Here, the authors report an O-glycoside β-eliminase from Agrobacterium tumefaciens that converts the C3-oxidized O-β-d-glucoside of phloretin into the aglycone and the 2-hydroxy-3-keto-d-glycal elimination product, and suggest convergent evolution of β-eliminase active sites for the cleavage of natural product 3-keto-O-glycosides.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Graz University of Technology, NAWI Graz, Institute of Biotechnology and Biochemical Engineering, Graz, Austria (GRID:grid.410413.3) (ISNI:0000 0001 2294 748X)
2 Graz University of Technology, NAWI Graz, Institute of Biotechnology and Biochemical Engineering, Graz, Austria (GRID:grid.410413.3) (ISNI:0000 0001 2294 748X); Austrian Centre of Industrial Biotechnology, Graz, Austria (GRID:grid.432147.7) (ISNI:0000 0004 0591 4434)
3 University of Graz, NAWI Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003)
4 University of Graz, NAWI Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003); BioTechMed-Graz, Graz, Austria (GRID:grid.452216.6); University of Graz, BioHealth Field of Excellence, Graz, Austria (GRID:grid.5110.5) (ISNI:0000 0001 2153 9003)
5 Medical University of Graz, Laboratory of Computer-Aided Molecular Design, Division of Medicinal Chemistry, Otto-Loewi Research Center, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476)